Clinical Outcomes of Lobular Carcinoma In Situ: Risk of Invasive Cancer Development
- Author:
Doyoun WOEN
1
;
Ki Jo KIM
;
Su Min LEE
;
Seungah LEE
;
Kawon OH
;
Cho Eun LEE
;
Seok Jin NAM
;
Seok Won KIM
;
Jeong Eon LEE
;
Byung Joo CHAE
;
Se Kyung LEE
;
Jai Min RYU
;
Woong Ki PARK
;
Hyunwoo LEE
;
Jonghan YU
Author Information
- Publication Type:Original Article
- From:Journal of Breast Cancer 2026;29(2):163-174
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Lobular carcinoma In Situ (LCIS) is a noninvasive lesion associated with an increased risk of invasive cancer. Since its removal from the tumor, node, metastasis classification in the 8th edition of the American Joint Committee on Cancer (AJCC) guidelines, the clinical management of LCIS has shifted from surgery to surveillance. However, studies focusing on the risk and associated factors for invasive cancer development in pure LCIS without ductal carcinoma In Situ (DCIS) or invasive cancer remain limited.
Methods:We retrospectively analyzed 106 patients diagnosed with pure LCIS between 2008 and 2018. This study evaluated the effect of tamoxifen use and histologic type on the development of invasive cancer.
Results:All 106 patients underwent surgery, and nine (8.5%) developed invasive cancer over a median follow-up of 67.5 months. The incidence of invasive cancer was lower in the tamoxifen group (6.3%, n = 4) than in the non-tamoxifen group (11.9%, n = 5), although this difference was not statistically significant (p = 0.266). Pleomorphic LCIS had a significantly higher incidence of invasive cancer (30.0%, n = 3) than classic LCIS (6.3%, n = 6) (p = 0.045).Multivariable Cox regression analysis showed no significant difference in the risk of invasive cancer according to tamoxifen use (hazard ratio [HR], 2.031; 95% confidence interval [CI], 0.544–7.579; p = 0.292). However, pleomorphic LCIS showed a trend toward an increased risk of invasive cancer compared to classic LCIS (HR, 3.856; 95% CI, 0.922–16.126; p = 0.064).
Conclusion:Postoperative tamoxifen did not significantly lower invasive cancer development in patients with pure LCIS. Pleomorphic LCIS may carry a higher risk than classic LCIS. These findings require tailored follow-up and treatment strategies based on the histologic subtype of LCIS.
